FDA Approved: IBSRELA — Supplemental Application (Ardelyx, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for IBSRELA (tenapanor hydrochloride) submitted by Ardelyx, Inc., under NDA 211801.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome with Constipation

Drugs mentioned

• IBSRELA (tenapanor hydrochloride)

Snippet

SUPPL AP for IBSRELA (TENAPANOR HYDROCHLORIDE)